Company Filing History:
6 out of 25 
1 out of 1,381 
Years Active: 2014-2021
Title: Innovator John Kinzell: Advancing Peptide Drug Formulations
Introduction: John Kinzell, an innovative inventor based in San Rafael, California, has made significant contributions to the field of biopharmaceuticals. With a total of six patents to his name, Kinzell's work primarily focuses on developing stable formulations for parenteral injection of peptide drugs. His research aims to improve the safety and efficacy of treatments for conditions such as hypoglycemia.
Latest Patents: Kinzell's most recent patents highlight his commitment to enhancing pharmaceutical delivery methods. One of his notable inventions includes stable formulations for parenteral injection of glucagon, specifically designed to treat hypoglycemia. These formulations provide minimal pain administration through concentrated injections that are pharmaceutically acceptable. Another significant patent addresses stable glucagon formulations for the treatment of severe hypoglycemia in emergency situations, demonstrating Kinzell's focus on urgent medical needs.
Career Highlights: Kinzell has an impressive background in the pharmaceutical industry, having worked with Xeris Pharmaceuticals, Inc. and the University of Colorado. His expertise in biopharmaceuticals has positioned him as a key player in the development of innovative solutions for drug delivery.
Collaborations: Throughout his career, Kinzell has collaborated with talented individuals in the field, including Steven J. Prestrelski and Wei-Jie Fang. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion: John Kinzell is a pioneering inventor whose work in stable formulations for peptide drugs continues to impact the pharmaceutical landscape. His dedication to improving treatment methods for hypoglycemia through innovative delivery systems exemplifies his role as a leading figure in biopharmaceutical research. With an impressive patent portfolio and meaningful collaborations, Kinzell is poised to make further advancements in the field.